Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMQ1GH4)

Drug Name
AEF0117 Drug Info
Indication
Disease Entry ICD 11 Status REF
Marijuana use disorder 6C41 Phase 2 [1]
Cross-matching ID
PubChem CID
139433957
TTD Drug ID
DMQ1GH4

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cannabinoid receptor 1 (CB1) TT6OEDT CNR1_HUMAN Antagonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Cannabinoid receptor 1 (CB1) DTT CNR1 2.907 4.667 2.982 3.678
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Marijuana use disorder
ICD Disease Classification 6C41
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cannabinoid receptor 1 (CB1) DTT CNR1 5.59E-02 -0.22 -0.45
Cannabinoid receptor 1 (CB1) DTT CNR1 7.68E-01 -0.06 -0.46
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03717272) Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Affimed Therapeutics.